November 1, 2022 | Targeted Therapies in Oncology

Frontline Nivolumab/Ipilimumab + Chemotherapy Benefit Extends to Histology and PD-L1 Subgroups in mNSCLC

November 19, 2022

Clinical Articles

Updated data from the phase 3 CheckMate 9LA trial showed that the combination of nivolumab, ipilimumab, and 2 cycles of chemotherapy elicited survival benefit in patients with treatment-naïve metastatic non–small cell lung cancer.

Cemiplimab Makes Case as First-Line, Nonchemotherapy Treatment in Metastatic NSCLC

November 18, 2022

Clinical Articles

Updated results of the EMPOWER-Lung1 trial of cemiplimab in patients advanced or metastatic non–small cell lung cancer showed improvements in overall survival, progression-free survival, and overall response rate.